Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis

Pancreatology

Volumn 10, Issue 6, 2011, Pages 689-694

  Talar Wojnarowska, Renata ^a,c   Gasiorowska, Anita ^a   Olakowski, Marek ^b   Lekstan, Andrzej ^b   Lampe, Paweł ^b   Malecka Panas, Ewa ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c Department of Digestive Tract Diseases ^*  (Poland)

Author keywords

CA19 9; Chronic pancreatitis; Neopterin; Pancreatic adenocarcinoma; Tissue polypeptide specific antigen

Indexed keywords

CA 19-9 ANTIGEN; NEOPTERIN; TISSUE POLYPEPTIDE ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SIZE; CHRONIC PANCREATITIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISTANT METASTASIS; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 78651400829     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000320693     Document Type: Article

References (23)

1. Goonetilleke KS, Siriwardena AK: System-atic review of carbohydrate antigen (CA19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007; 33: 266-270. (Pubitemid 46488663)
2. Zhang S, Wang YM, Sun CD, Lu Y, Wu LQ: Clinical value of serum CA19-9 levels in evaluating respectability of pancreatic carci-noma. World J Gastroenterol 2008; 14: 3750-3753.
3. Bedi MM, Gandhi MD, Jacob G, Lekha V, Venuqopal A, Ramesh H: CA19-9 to differ-entiate benign and malignant masses in chronic pancreatitis: is there any benefit? In-dian J Gastroenterol 2009; 28: 24-27.
4. Sawabu N, Watanabe H, Yamaguchi Y, Oh-tsubo K, Motoo Y: Serum tumor markers and molecular biological diagnosis in pancreatic cancer. Pancreas 2004; 28: 263-267. (Pubitemid 38437320)
5. Yildrim Y, Gunel N, Coskun U, Pasaoglu H, Aslan S, Cetin A: Serum neopterin level in patients with breast cancer. Med Oncol 2008; 25: 403-407.
6. Melichar B, Solichova D, Melicharova K, Malirova E, Cermanova M, Zadak Z: Uri-nary neopterin in patients with advanced colorectal carcinoma. Int J Biol Markers 2006; 21: 190-198. (Pubitemid 44660292)
7. Murr C, Widner B, Wirleitner B, Fuchs D: Neopterin as a marker for immune system activation. Curr Drug Metab 2002; 3: 175-187. (Pubitemid 34326529)
8. Unal B, Kocer B, Altun B, Surmeli S, Aksaray S, Balci M, Ozlu B, Cengiz O: Serum neop-terin as a prognostic indicator in patients with gastric carcinoma. J Invest Surg 2009; 22: 419-425.
9. Piecuch J, Rudzki M, Orkisz W, Swietochowska E, Wielkoszynski T, Waniczek D, Arendt J, Sosada K, Zurawinski W, Ładny JR: Neopterin-a potential factor for differentia-tion between pancreatic cancer and chronic pancreatitis. Hepatogastroenterology 2008; 55: 258-261. (Pubitemid 351462204)
10. Birk D, Gansauge F, Gansauge S, Schwarz A, Beger HG: Levels of serum neopterin are in-creased in pancreatic cancer patients and correlate with the prognosis. Eur J Med Res 1999; 4: 156-160.
11. Slesak D, Harlozinska-Szmyrka A, Knast W, Sedlaczek P, Einarsson R, van Dalen A: TPS and CA19-9 measurement in the follow-up of patients with pancreatic cancer and chronic pancreatitis. Int J Biol Markers 2004; 19; 115-119. (Pubitemid 39106936)
12. Sandblom G, Granroth S, Ramussen IC: TPS, CA19-9, VEGF-A and CEA as diagnostic and prognostic factors in patients with mass le-sions in the pancreatic head. Upsala J Med Sci 2008; 113: 57-64.
13. Slesak D, Harlozinska-Szmyrka A, Knast W, Sedlaczek P, van Dalen A, Einarsson R: Tis-sue polypeptide-specific antigen, a marker for differentiation between pancreatic carci-noma and chronic pancreatitis. Cancer 2000; 89: 83-88. (Pubitemid 30451277)
14. Yeh LS, Hung YC, Kao A, Lin CC, Lee CC: Tissue polypeptide-specific antigen and car-bohydrate antigen 125 in the early prediction of recurrent ovarian cancer. Anticancer Res 2002; 22: 3669-3671. (Pubitemid 36132847)
15. Hwa HL, Kuo WH, Chang LY, Wang MY, Tung TH, Chang KJ, Hsieh FJ: Prediction of breast cancer and ly mph node metastatic sta-tus with tumour markers using logistic re-gression models. J Eval Clin Pract 2008; 14: 275-280.
16. Pasanen PA, Eskelinen M, Partanen K, Pik-karainen P, Penttila I, Alhava E: Diagnostic value of tissue polypeptide-specific antigen in patients with pancreatic carcinoma. Tu-mour Biol 1994; 15: 52-60. (Pubitemid 24122944)
17. Plebani M, Basso D, Del Favero G, Ferrara C, Meggiato T, Fogar P, Mangano F, Ricciardi G, Burlina A: Clinical utility of TPS, TPA and CA19-9 measurement in pancreatic can-cer. Oncology 1993; 50: 436-440. (Pubitemid 23323712)
18. Kawa S, Tokoo M, Haebe O, Hayashi K, Imai H, Oguchi H, Kiyosawa K, Furuta S, Homma T: Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer. Br J Cancer 1994; 70: 481-486. (Pubitemid 24268551)
19. Banfi G, Zerbi A, Pastori S, Parolini D, Di Carlo V, Bonini P: Behavior of tumor mark-ers CA19-9, CA195, CAM43, CA243 and TPS in the diagnosis and follow-up of pan-creatic cancer. Clin Chem 1993; 39: 420-423. (Pubitemid 23099006)
20. Joergensen MT, Heegard NH, Schaffalitzky de Muckadell OB: Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer. Pancreas 2010; 39: 243-247.
21. Manes G, Spada OA, Rabitti PG, Feola B, Misso S, Minerva A, Uomo G: Neopterin se-rum levels in pancreatic adenocarcinoma. Int J Pancreatol 1999; 25: 31-37. (Pubitemid 29161564)
22. Sahin TT, Yuksel O, Girgin G, Sipahi H, Dikmen K, Azili C, Taneri F, Baydar T: Is neop-terin level a predictive and differential bio-marker in patients with thyroid disorders? J Endocrinol Invest 2009; 32: 147-149.
23. Treska V, Topolcan O, Stanislav K, Liska V, Holubec L: Preoperative tumor markers as prognostic factors of colorectal liver metas-tases. Hepatogastroenterology 2009; 56: 317-320.